Skip to main content
Signal8
Launch Terminal
Tourangeau Greg profile photo

Greg Tourangeau

CIK: 0001916566

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)1 (33.3%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (66.7%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

Fulcrum Therapeutics, Inc. logo
FULC

Fulcrum Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (3 total)

  • Fulcrum Therapeutics, Inc. logo
    FULC

    Fulcrum Therapeutics, Inc.

    Feb 2, 2026
    Award(A)

    Stock Option (right to buy)

    Direct
    57K shares-
  • Fulcrum Therapeutics, Inc. logo
    FULC

    Fulcrum Therapeutics, Inc.

    May 8, 2025
    Sale(S)
    Direct
    498 shares at avg. $5.06$3K
  • Fulcrum Therapeutics, Inc. logo
    FULC

    Fulcrum Therapeutics, Inc.

    Jan 24, 2025
    Award(A)

    Stock Option (right to buy)

    Direct
    76.1K shares-

1-3 of 3

About Tourangeau Greg

Tourangeau Greg (SEC CIK 0001916566) files insider reports with the SEC as Principal Accounting Officer of Fulcrum Therapeutics, Inc. (FULC).

Signal8 holds 3 ownership filings by Tourangeau Greg, all Form 4s, filed between Jan 28, 2025 and Feb 4, 2026. Those filings report 3 transactions, from Jan 24, 2025 to Feb 2, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Tourangeau Greg's filings is in CAMBRIDGE, MA.

Recent filings by Tourangeau Greg

  • Feb 2, 2026: Grant or award of FULC derivative securities (Form 4, code A).
  • May 8, 2025: Open-market sale of FULC shares (Form 4, code S).
  • Jan 24, 2025: Grant or award of FULC derivative securities (Form 4, code A).

Other insiders filing for Fulcrum Therapeutics, Inc. (FULC)

How to read Form 4 transaction codes